Stablix and Vertex Establish Strategic Collaboration to Discover and Develop Targeted Protein Stabilization Therapeutics NEW YORK and BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced a...

Stablix to Present at Wells Fargo 2023 Targeted Protein Degradation Summit NEW YORK, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Kevin...

Stablix Appoints Douglas Williams, Ph.D., to Board of Directors NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the...